Transcription–replication conflicts (TRCs), arising from spatiotemporal interference between transcription and replication machinery, are major sources of genome instability in cell. In pancreatic ductal adenocarcinoma (PDAC), oncogenic KRAS promotes TRC formation, and pharmacological exacerbation of endogenous T...
Fan Meng, Tony Fernandez, C. Luan et al.· Cancer Research· 0 citations
These findings establish RAS-pathway focused combinatorial CRISPR screening as a robust approach for identifying clinically actionable combination vulnerabilities and nominate FGFR signaling as a lineage-specific mediator of KRAS inhibitor resistance in PDAC.
R. Ebright, Yao He, Alan Zhang et al.· Cancer Research· 0 citations
Oncogenic KRAS drives >90% of pancreatic ductal adenocarcinoma (PDAC), and the pan-RAS inhibitor daraxonrasib doubles overall survival, but adaptive and acquired resistance limit the depth and duration of responses. To systematically map combination vulnerabilities, we developed RAS+, a digenic CRISPR knockout library...
R. Ebright, Yao He, Alan Zhang et al.· bioRxiv· 0 citations
Inhibiting pan-RAS(on) RAS-GTP with daraxonrasib, alone or in combination with a MEK inhibitor, provides a new strategy for the treatment of TNBC that inhibits RTK activation of the RAS-RAF-MEK-ERK pathway and tumor proliferation.
Michael P. East, J. Olivares-Quintero, D. Okumu et al.· bioRxiv· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.